These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 19488074)
1. Peptide-receptor radionuclide therapy for endocrine tumors. van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807 [TBL] [Abstract][Full Text] [Related]
3. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653 [TBL] [Abstract][Full Text] [Related]
4. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893 [TBL] [Abstract][Full Text] [Related]
5. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Kwekkeboom DJ; Krenning EP Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376 [TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608 [TBL] [Abstract][Full Text] [Related]
8. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Bodei L; Kidd M; Prasad V; Modlin IM Front Horm Res; 2015; 44():198-215. PubMed ID: 26303714 [TBL] [Abstract][Full Text] [Related]
9. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935 [TBL] [Abstract][Full Text] [Related]
10. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT. Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369 [TBL] [Abstract][Full Text] [Related]
11. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631 [TBL] [Abstract][Full Text] [Related]
12. Radionuclide Therapy for Neuroendocrine Tumors. Cives M; Strosberg J Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446 [TBL] [Abstract][Full Text] [Related]
13. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Bodei L; Pepe G; Paganelli G Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546 [TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296 [TBL] [Abstract][Full Text] [Related]
15. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; de Herder WW; Krenning EP Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418 [TBL] [Abstract][Full Text] [Related]
17. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors. Giovacchini G; Nicolas G; Forrer F Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758 [TBL] [Abstract][Full Text] [Related]
18. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Minczeles NS; Hofland J; de Herder WW; Brabander T Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177 [TBL] [Abstract][Full Text] [Related]